secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001213900-24-059821
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15
--------------------------------------------------------------------------------

- License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
- Agreement includes initial and annual fees from low to mid five figures, milestone payments, and royalties on net revenues.
- Silo submitted a pre-IND briefing package to FDA and plans 505(b)(2) pathway to shorten clinical timelines and reduce costs.
- Term runs per country/product until later of patent expiry, 20 years after first commercial sale, or end of market exclusivity.
- CEO Eric Weisblum states the license is a critical step that could increase shareholder value subject to FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024059821/0001213900-24-059821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024059821/ea0209059-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-059821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer